The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for dupilumab to treat adults with bullous pemphigoid.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback